Nexalin Technology (NXL) Consolidated Net Income (2021 - 2026)
Nexalin Technology (NXL) posted Consolidated Net Income of -$2.2 million for Q2 2026, down 6.79% on a QoQ basis from -$2.1 million in Q1 2026, and down 41.63% year-over-year from -$3.8 million in Q2 2025.
Analysis
Nexalin Technology (NXL) Consolidated Net Income (2021 - 2026) Analysis & Trends
Nexalin Technology has reported Consolidated Net Income for 6 years, with the latest figure at -$2.2 million in Q2 2026.
- On a quarterly basis, Consolidated Net Income fell 41.63% year-over-year to -$2.2 million in Q2 2026; TTM through Jun 2026 was -$9.0 million, a 1.57% decrease from a year earlier, with the FY2025 full-year figure at -$6.5 million, up 14.67% from the prior year.
- Consolidated Net Income was -$2.2 million for Q2 2026 at Nexalin Technology, down from -$2.1 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$303646.0 in Q3 2022, with the low at -$2.8 million in Q4 2024.
- Average Consolidated Net Income over 5 years is -$1.5 million, with a median of -$1.4 million recorded in 2024.
- The sharpest annual moves came in 2022 and 2023: Consolidated Net Income surged 83.34% in 2022, then sank 656.54% in 2023.
- Over 5 years, Consolidated Net Income stood at -$736919.0 in 2022, then fell by 5.94% to -$780669.0 in 2023, then plunged by 262.95% to -$2.8 million in 2024, then climbed by 16.12% to -$2.4 million in 2025, then advanced by 5.79% to -$2.2 million in 2026.
- The last three Consolidated Net Income figures came in at -$2.2 million (Q2 2026), -$2.1 million (Q1 2026), and -$2.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | -2.24 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.24 Mn |
| Mar 31, 2026 | -2.10 Mn |
| Dec 31, 2025 | -2.38 Mn |
| Sep 30, 2025 | -2.28 Mn |
| Jun 30, 2025 | -1.58 Mn |
| Mar 31, 2025 | -1.99 Mn |
| Dec 31, 2024 | -2.83 Mn |
| Sep 30, 2024 | -2.45 Mn |
| Jun 30, 2024 | -1.28 Mn |
| Mar 31, 2024 | -1.05 Mn |
| Dec 31, 2023 | -780,669.00 |
| Sep 30, 2023 | -2.30 Mn |
| Jun 30, 2023 | -822,437.00 |
| Mar 31, 2023 | -748,414.00 |
| Dec 31, 2022 | -736,919.00 |
| Sep 30, 2022 | -303,646.00 |
| Jun 30, 2022 | -445,103.00 |
| Mar 31, 2022 | -393,249.00 |
| Dec 31, 2021 | -595,928.00 |
| Sep 30, 2021 | -1.82 Mn |